Trial · NCT02463409
Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
NCT02463409, Phase 2, Completed, Vanderbilt University Medical Center; results first posted 2017-05-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy). Trials, record NCT02463409. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02463409
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)
- NCT number
- NCT02463409
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Vanderbilt University Medical Center
- Conditions
- Pseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
- Interventions
- Theophylline
- First posted
- 2015-06-04
- Last updated
- 2017-06-26
- Results first posted
- 2017-05-30
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Urine cAMP | 1 day | Change in urine cAMP (after parathyroid hormone stimulation) before and during treatment with theophylline |
| Secondary | Change in Resting Energy Expenditure (REE) | 1 day | Change in REE before and during treatment with theophylline |
| Secondary | Change in Apnea Hypopnea Index (AHI) | 1 day | Change in AHI before and during treatment with theophylline |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Urine cAMP | 1 day | Patients treated with theophylline who maintained appropriate IV access. Only 3 patients had complete data available. | fm/uL | MEAN |
| SECONDARY | Change in Resting Energy Expenditure (REE) | 1 day | kcals per day | MEAN | |
| SECONDARY | Change in Apnea Hypopnea Index (AHI) | 1 day | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Urine cAMP | Theophylline | 3048 | Standard Deviation 8369 | fm/uL | |
| Change in Resting Energy Expenditure (REE) | Theophylline | -14 | Standard Error 68 | kcals per day | |
| Change in Apnea Hypopnea Index (AHI) | Theophylline | -0.60 | Standard Error 0.67 | units on a scale |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Theophylline | 6 | |
| Overall Study | COMPLETED | Theophylline | 4 | |
| Overall Study | NOT COMPLETED | Theophylline | 2 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Theophylline | 3 | 5 | 3 |
| other | Headache | Nervous system disorders | Theophylline | 3 | 5 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Theophylline | 1 | 5 | 1 |
| other | Tachycardia | Cardiac disorders | Theophylline | 1 | 5 | 1 |
| other | dizziness | Nervous system disorders | Theophylline | 1 | 5 | 1 |
| other | Vomiting | Gastrointestinal disorders | Theophylline | 1 | 5 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Theophylline | 0 | 5 |
| Total, other adverse events | Theophylline | 4 | 5 |
| Total, serious adverse events | Theophylline | 0 | 5 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02463409
GET https://conductscience.org/api/trials/v1/NCT02463409/registered